HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY 01)

Clinical Trial ID NCT01683188

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pathways and therapeutic targets in melanoma.	Oncotarget	2014	1.17
2	Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.	Front Immunol	2015	1.04
3	Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.	Mol Cancer Ther	2014	0.92
4	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.	Drug Des Devel Ther	2014	0.91
5	Understanding the biology of melanoma and therapeutic implications.	Hematol Oncol Clin North Am	2014	0.85
6	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.	Semin Oncol	2015	0.82
7	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.	J Transl Med	2014	0.80
8	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.	Ther Adv Med Oncol	2015	0.78
9	Update on use of aldesleukin for treatment of high-risk metastatic melanoma.	Immunotargets Ther	2015	0.76
10	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.	Trends Immunol	2016	0.75